Literature DB >> 526402

Open evaluation of labetalol in the treatment of angina pectoris occurring in hypertensive patients.

E M Besterman, M Spencer.   

Abstract

1 In nine hypertensive subjects with angina pectoris, labetalol diminished the incidence of chest pain occurring spontaneously or induced by exercise. 2 Labetalol lowered BP in all subjects. 3 Exercise tolerance at maximum levels was increased by labetalol. 4 Improved cardiac function by labetalol may be related to decreased afterload on the left ventricle, and diminished oxygen utilization by the myocardium.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 526402      PMCID： PMC1429738     

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  3 in total

1.  Closing remarks: current status of labetalol.

Authors:  C T Dollery
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

2.  Reflex increase in coronary vascular resistance in patients with ischemic heart disease.

Authors:  G H Mudge; W Grossman; R M Mills; M Lesch; E Braunwald
Journal:  N Engl J Med       Date:  1976-12-09       Impact factor: 91.245

Review 3.  Pharmacological effects of labetalol in man.

Authors:  D A Richards
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335
  3 in total
  6 in total

1.  Labetalol, an alpha- and beta-adrenoceptor-blocking agent: its use in therapeutics. A summary of the symposium.

Authors:  B N Prichard; D A Richards
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

2.  Alternatives to beta-blockade in therapy of hypertension with angina pectoris: role of nifedipine or of labetalol.

Authors:  L H Opie; D White; J Lee; W F Lubbe
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

Review 3.  Alpha- and beta-blockade in angina pectoris.

Authors:  S H Taylor
Journal:  Drugs       Date:  1984       Impact factor: 9.546

Review 4.  Role of vasodilation in the antihypertensive and antianginal effects of labetalol: implications for therapy of combined hypertension and angina.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-09       Impact factor: 3.727

5.  Diazoxide and labetalol in acute hypertension during haemodialysis.

Authors:  G Keusch; H Schiffl; U Binswanger
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

6.  Comparative haemodynamic dose response effects of propranolol and labetalol in coronary heart disease.

Authors:  B Silke; G I Nelson; R C Ahuja; S H Taylor
Journal:  Br Heart J       Date:  1982-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.